{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=4",
    "query": {
      "intervention": "TMZ",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 469,
    "total_pages": 47,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T08:26:44.839Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00574964",
      "title": "Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Gliadel Wafer, Temodar and Radiotherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 50,
      "start_date": "2005-10",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2016-10-27",
      "last_synced_at": "2026-10-18T08:26:44.839Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574964"
    },
    {
      "nct_id": "NCT01480479",
      "title": "Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glioblastoma",
        "Small Cell Glioblastoma",
        "Giant Cell Glioblastoma",
        "Gliosarcoma",
        "Glioblastoma With Oligodendroglial Component"
      ],
      "interventions": [
        {
          "name": "Rindopepimut (CDX-110) with GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "KLH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 745,
      "start_date": "2011-11",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-10-18T08:26:44.839Z",
      "location_count": 88,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 74 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01480479"
    },
    {
      "nct_id": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Astrocytoma, IDH-Mutant",
        "Glioblastoma, IDH-wildtype",
        "Brain Metastases, Adult",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Esophageal Squamous Cell Carcinoma",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Microsatellite Instability-High Solid Malignant Tumor",
        "Mismatch Repair Deficient Solid Malignant Tumor",
        "Microsatellite Instability-High Colorectal Cancer",
        "Mismatch Repair Deficient Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Small Cell Lung Cancer",
        "Squamous Cell Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "NEO212 Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI Protocol",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neonc Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2023-11-01",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-18T08:26:44.839Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06047379"
    },
    {
      "nct_id": "NCT03728361",
      "title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Grade I Neuroendocrine Carcinoma",
        "Grade II Neuroendocrine Carcinoma",
        "Grade III Neuroendocrine Carcinoma",
        "Metastatic Neuroendocrine Carcinoma",
        "Neuroendocrine Carcinoma",
        "Recurrent Small Cell Lung Carcinoma",
        "Refractory Small Cell Lung Carcinoma",
        "Lung Cancer Stage IV",
        "Large Cell Neuroendocrine Carcinoma",
        "Neuroendocrine Tumors",
        "Small Cell Lung Cancer Metastatic",
        "Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Dwight Owen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2018-12-31",
      "completion_date": "2025-12-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-18T08:26:44.839Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03728361"
    },
    {
      "nct_id": "NCT00068250",
      "title": "Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "temozolomide 100 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "temozolomide 150 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "temozolomide 200 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "post-radiation therapy temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2003-07",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-02-07",
      "last_synced_at": "2026-10-18T08:26:44.839Z",
      "location_count": 26,
      "location_summary": "Jacksonville, Florida • Jacksonville Beach, Florida • Orange Park, Florida + 17 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville Beach",
          "state": "Florida"
        },
        {
          "city": "Orange Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068250"
    },
    {
      "nct_id": "NCT00813943",
      "title": "Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Cilengitide (2-times weekly)",
          "type": "DRUG"
        },
        {
          "name": "cilengitide (5-times weekly)",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 265,
      "start_date": "2009-03",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-10-18T08:26:44.839Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00813943"
    },
    {
      "nct_id": "NCT04239092",
      "title": "9-ING-41 in Pediatric Patients With Refractory Malignancies.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Cancer",
        "Refractory Neoplasm",
        "Cancer Pediatric",
        "Refractory Tumor",
        "Pediatric Cancer",
        "Pediatric Brain Tumor",
        "Neuroblastoma",
        "Neuroblastoma Recurrent",
        "Pediatric Lymphoma",
        "Pediatric Meningioma",
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "9-ING-41",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actuate Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "Up to 22 Years"
      },
      "enrollment_count": 40,
      "start_date": "2020-06-05",
      "completion_date": "2025-07-07",
      "has_results": false,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-10-18T08:26:44.839Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04239092"
    },
    {
      "nct_id": "NCT07223034",
      "title": "A Study of 177Lu-PSMA-617 in People With Gliomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma",
        "Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)",
        "Glioblastoma, IDH-wildtype",
        "Diffuse Midline Glioma, H3 K27-Altered",
        "Diffuse Hemispheric Glioma, H3 G34-mutant",
        "Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "177Lu-PSMA-617",
          "type": "DRUG"
        },
        {
          "name": "68Ga-PSMA-PET scan/ MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Quality of Life Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-10-27",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-18T08:26:44.839Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223034"
    },
    {
      "nct_id": "NCT02392793",
      "title": "Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Talazoparib",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Peg-filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "12 Months to 25 Years"
      },
      "enrollment_count": 43,
      "start_date": "2015-03-25",
      "completion_date": "2019-08-30",
      "has_results": false,
      "last_update_posted_date": "2021-02-09",
      "last_synced_at": "2026-10-18T08:26:44.839Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02392793"
    },
    {
      "nct_id": "NCT00275067",
      "title": "Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "arsenic trioxide",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2005-05",
      "completion_date": "2021-05",
      "has_results": false,
      "last_update_posted_date": "2020-02-25",
      "last_synced_at": "2026-10-18T08:26:44.839Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Naperville, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Naperville",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00275067"
    }
  ]
}